Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose CEP With Stem Cell Rescue in Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00002521Phase 2Completed
- Sponsor
- Temple University
- Start
- Feb 1993
- Primary completion
- Feb 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, etoposide and cisplatin in non-Hodgkin lymphoma (NHL), sponsored by Temple University. Primary endpoints: Overall Response Rate and Overall Survival. Started Feb 1993; status: completed.
02
Drugs
cyclophosphamideetoposidecisplatin
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00002521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002521.